Arvinas (NASDAQ:ARVN) Stock Price Expected to Rise, Oppenheimer Analyst Says

Arvinas (NASDAQ:ARVN) had its price target lifted by equities researchers at Oppenheimer from $40.00 to $45.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s price target points to a potential upside of 151.49% from the stock’s current price.

ARVN has been the subject of several other reports. Barclays decreased their price objective on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. BTIG Research assumed coverage on Arvinas in a report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price target for the company. Guggenheim reissued a “buy” rating and issued a $57.00 price objective on shares of Arvinas in a research note on Wednesday. Wedbush restated an “outperform” rating and set a $57.00 target price on shares of Arvinas in a research report on Tuesday. Finally, Stifel Nicolaus lowered their target price on Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $59.58.

Arvinas Stock Performance

Shares of ARVN traded up $0.21 during trading hours on Wednesday, reaching $17.89. The stock had a trading volume of 471,030 shares, compared to its average volume of 875,855. Arvinas has a 12 month low of $16.61 and a 12 month high of $53.08. The stock has a market capitalization of $1.23 billion, a PE ratio of -3.84 and a beta of 1.88. The company’s 50-day moving average is $19.33 and its two-hundred day moving average is $23.36.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. During the same quarter last year, the business posted ($2.53) EPS. Equities analysts anticipate that Arvinas will post -3.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Arvinas

Hedge funds and other institutional investors have recently made changes to their positions in the business. nVerses Capital LLC bought a new stake in Arvinas in the 3rd quarter worth about $39,000. KBC Group NV boosted its stake in shares of Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after buying an additional 1,255 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Arvinas by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after acquiring an additional 440 shares in the last quarter. Quantbot Technologies LP increased its position in shares of Arvinas by 147.3% during the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after acquiring an additional 2,601 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its position in shares of Arvinas by 37.0% during the third quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock valued at $164,000 after acquiring an additional 1,798 shares during the last quarter. 95.19% of the stock is owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.